Yanwen Jiang
Scientist Genentech
Yanwen Jiang, Ph.D., is a distinguished scientist with a strong background in developing novel biomarker tools for drug development in blood cancers (CLL, DLBCL, MM) at Roche/Genentech. Dr. Jiang is known for using Measurable Residual Disease (MRD) as a new way to develop drugs, leveraging it to evaluate treatment effectiveness and guide clinical trial design. His work focuses on implementing liquid biopsy biomarker tools in large global randomized clinical trials, generating insights to support the use of MRD/ctDNA in patient stratification and prognostication, fostering industry/academic collaboration to drive MRD surrogate endpoint development, and employing these novel approaches to facilitate fast drug development.
Seminars
Bridging assay development and translational research to define clinically meaningful MRD cutoffs and endpoints
Designing MRD-guided clinical trials to inform treatment decisions, including escalation, consolidation & de-escalation strategies
Addressing turnaround time, cost and implementation challenges to ensure MRD assays can move fri om trials into routine practice
